Targeted drug for lung cancer with liver tumors and T790M-like resistance
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called EDB-102 for people with a specific type of advanced lung cancer (NSCLC) that has spread to the liver, has a particular EGFR L858R gene change, and has stopped responding to a later-generation targeted therapy called osimertinib. The goal is to see if EDB-102 is safe and may help shrink liver tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years old.
- Advanced lung cancer that has spread to the liver, confirmed by biopsy.
- You must have taken and progressed on a third-generation cancer pill (like osimertinib).
- Your cancer must have a specific gene change called EGFR L858R, confirmed in a recent tissue or blood sample.
- You have at least one liver tumor that can be measured on scans.
- You must be in fairly good health (able to do daily activities, with adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests whether adding SYS6010 to osimertinib before surgery works better than osimertinib alone for people with a type of lung cancer that has an EGFR mutation. The goal is to shrink the tumor and improve surgery outcomes.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This trial tests a new drug (ANS014004) combined with an EGFR-targeted therapy for people with advanced non-small cell lung cancer that has an EGFR mutation. It is for those whose cancer has gotten worse after standard treatments or who cannot take them.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.